Silo Pharma Inc (SILO)

$0.61 +0.01 (1.63%)
Market Cap 5.74M
Revenue (ttm) 70,000.00
Net Income (ttm) -4.39M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -6,271.43%
Debt to Equity Ratio 0.00
Volume 156,300
Avg Vol 465,992
Day's Range N/A - N/A
Shares Out 9.40M
Stochastic %K 23%
Beta 0.30
Analysts Strong Sell
Price Target $10.00

Company Profile

Silo Pharma Inc. operates as a developmental stage biopharmaceutical company. The company is developing therapeutics that address underserved conditions, including post-traumatic stress disorder (PTSD), stress-induced anxiety disorders, fibromyalgia, and central nervous system (CNS) diseases. It focuses on developing traditional therapies and psychedelic treatments in formulations. The company's lead program, SPC-15, is an intranasal treatment targeting PTSD and stress-induced anxiety disorders....

Industry: Biotechnology
Sector: Healthcare
Phone: 718 400 9031
Address:
677 North Washington Boulevard, Sarasota, United States
RealYOW
RealYOW Sep. 6 at 4:14 AM
$SILO who dat?
0 · Reply
DocHooli
DocHooli Sep. 5 at 10:16 PM
$SILO is my lead candidate for the Galaxy, Jump Crypto, and Multicoin Solana DAT. Establishing a crypto advisory board with Corwin Yu who does business with all major exchanges including $GLXY he understands how DATs work. No debt, no significant shareholders, very decent smart board people already. Obviously this is my thinking it makes sense to me but maybe not for the leaders of those companies. It’s very narrow though there are only maybe 6 potential take over targets below a 30Mil market cap. This one is top for sure.
1 · Reply
Jbjb90
Jbjb90 Sep. 3 at 3:44 PM
$SILO https://www.stocktitan.net/news/SILO/silo-pharma-secures-australian-patent-covering-licensed-ptsd-drug-1433dpdh3807.html
0 · Reply
onestudy
onestudy Sep. 3 at 1:36 PM
$SILO Patent news out on the company website this morning for its intranasal PTSD drug. 💪🚀
0 · Reply
premarketmaker
premarketmaker Sep. 3 at 12:28 PM
$SILO .715 PM HOD
0 · Reply
Thestocktraderhubzee
Thestocktraderhubzee Sep. 3 at 12:26 PM
$SILO Silo Pharma Secures Patent For PTSD Treatment SPC-15 Through Columbia University Partnership
0 · Reply
NVDAMillionaire
NVDAMillionaire Sep. 3 at 9:20 AM
$SILO Outstanding article that hits the mark on SILO's current state. So if you want to refresh your SILO insights or learn about SILO from scratch, this is a must read. https://beyondspx.com/quote/SILO/silo-pharma-s-bold-convergence-psychedelic-innovation-meets-digital-asset-ambition-nasdaq-silo#analysis
0 · Reply
onestudy
onestudy Sep. 2 at 12:41 PM
$SILO Elon Musk’s "DOGE lieutenant" took over Lykos, the US’s largest MDMA company, which aims to bring a psychedelic drug for PTSD to market under the Trump administration (The Guardian, Aug 28, 2025). $SILO is getting ready to submit IND application for its psychedelic based PTSD drug and has a connection with the Department of Veterans Affairs through the recent HOTH partnership.
0 · Reply
onestudy
onestudy Sep. 1 at 10:53 AM
$SILO Oregon Psilocybin Services (OPS), created under the Oregon Psilocybin Services Act, is moving forward with its 2025 rulemaking process. Key dates for psychedelic-related plays: 📝 Written Public Comment Period: Sept 2 – Sept 22, 2025 📢 Public Hearings: Sept 16 & Sept 18, 2025
0 · Reply
onestudy
onestudy Aug. 31 at 10:35 PM
$SILO Psychedelic drug, psilocybin, can reshape brain networks linked to negative thoughts, offering powerful potential for mental health treatments. From "New Scientist" (Aug 29, 2025)
0 · Reply
Latest News on SILO
Silo Pharma Secures Australian Patent Covering Licensed PTSD Drug Candidate Expanding Global IP Portfolio

Sep 3, 2025, 8:25 AM EDT - 5 days ago

Silo Pharma Secures Australian Patent Covering Licensed PTSD Drug Candidate Expanding Global IP Portfolio

Silo Pharma's Alzheimer's Candidate SPC-14 Featured in Leading Scientific Peer-reviewed Journal

Aug 21, 2025, 2:00 PM EDT - 17 days ago

Silo Pharma's Alzheimer's Candidate SPC-14 Featured in Leading Scientific Peer-reviewed Journal

Silo Pharma's PTSD Candidate SPC-15 Achieves Positive Safety Milestone, Paving Way for Accelerated Clinical Trials Under 505(b)(2) Pathway

Aug 19, 2025, 8:05 AM EDT - 20 days ago

Silo Pharma's PTSD Candidate SPC-15 Achieves Positive Safety Milestone, Paving Way for Accelerated Clinical Trials Under 505(b)(2) Pathway

Silo Pharma Appoints Crypto Infrastructure Pioneer Corwin Yu to Launch Institutional Bitcoin, Ethereum and Solana Treasury Platform

Aug 5, 2025, 8:32 AM EDT - 4 weeks ago

Silo Pharma Appoints Crypto Infrastructure Pioneer Corwin Yu to Launch Institutional Bitcoin, Ethereum and Solana Treasury Platform

Silo Pharma Announces Completion of Dosing in Safety Study of PTSD Drug SPC-15

Jul 16, 2025, 8:45 AM EDT - 7 weeks ago

Silo Pharma Announces Completion of Dosing in Safety Study of PTSD Drug SPC-15

Silo Pharma Advances PTSD Drug SPC-15 Toward Planned 2025 IND Submission with Pre-Clinical Study Data Expected in Q3 2025

Jul 7, 2025, 8:15 AM EDT - 2 months ago

Silo Pharma Advances PTSD Drug SPC-15 Toward Planned 2025 IND Submission with Pre-Clinical Study Data Expected in Q3 2025

Silo Pharma Enters into Letter of Intent to Form Joint Venture with Hoth Therapeutics to Develop Obesity Treatment Targeting $16 Billion Global Market

Jun 25, 2025, 8:38 AM EDT - 2 months ago

Silo Pharma Enters into Letter of Intent to Form Joint Venture with Hoth Therapeutics to Develop Obesity Treatment Targeting $16 Billion Global Market

Hoth Therapeutics (HOTH) and Silo Pharma (NASDAQ: SILO) today announced the formation of a 50/50 joint venture to develop a first-in-class GDNF-based therapy licensed from the U.S. Department of Veterans Affairs. The therapy targets obesity and fatty liver disease.

Jun 25, 2025, 8:27 AM EDT - 2 months ago

Hoth Therapeutics (HOTH) and Silo Pharma (NASDAQ: SILO) today announced the formation of a 50/50 joint venture to develop a first-in-class GDNF-based therapy licensed from the U.S. Department of Veterans Affairs. The therapy targets obesity and fatty liver disease.

HOTH

Silo Pharma Secures Biomarker Patent for Novel PTSD Therapeutic SPC-15 as Clinical Trial Nears

Jun 11, 2025, 9:00 AM EDT - 3 months ago

Silo Pharma Secures Biomarker Patent for Novel PTSD Therapeutic SPC-15 as Clinical Trial Nears

Silo Pharma Board of Directors Approves Purchase of Bitcoin as Treasury Reserve Asset

Jun 5, 2025, 9:15 AM EDT - 3 months ago

Silo Pharma Board of Directors Approves Purchase of Bitcoin as Treasury Reserve Asset

Silo Pharma Partners with Resyca for IND-Supporting Intranasal Drug-Device Study of PTSD Drug SPC-15

May 21, 2025, 8:55 AM EDT - 3 months ago

Silo Pharma Partners with Resyca for IND-Supporting Intranasal Drug-Device Study of PTSD Drug SPC-15

Silo Pharma Announces Closing of $2 Million Public Offering

May 16, 2025, 4:15 PM EDT - 4 months ago

Silo Pharma Announces Closing of $2 Million Public Offering

Silo Pharma Announces Pricing of $2 Million Public Offering

May 15, 2025, 9:15 AM EDT - 4 months ago

Silo Pharma Announces Pricing of $2 Million Public Offering

Silo Pharma Selects Veloxity Labs for Bioanalytical IND-Enabling Study for our Novel Intranasal PTSD Therapy, SPC-15

May 14, 2025, 4:07 PM EDT - 4 months ago

Silo Pharma Selects Veloxity Labs for Bioanalytical IND-Enabling Study for our Novel Intranasal PTSD Therapy, SPC-15

Silo Pharma Advances PTSD Drug SPC-15 Toward First-in-Human Trial with Key Safety Study Initiated at Frontage Laboratories

May 14, 2025, 8:40 AM EDT - 4 months ago

Silo Pharma Advances PTSD Drug SPC-15 Toward First-in-Human Trial with Key Safety Study Initiated at Frontage Laboratories

Silo Pharma's SP-26 Ketamine Implant Meets All Endpoints in Fibromyalgia Study

Apr 30, 2025, 8:11 AM EDT - 4 months ago

Silo Pharma's SP-26 Ketamine Implant Meets All Endpoints in Fibromyalgia Study

Silo Pharma Expands Intellectual Property Portfolio with Patent Application for Exclusively Licensed Alzheimer's Drug

Apr 28, 2025, 7:50 AM EDT - 4 months ago

Silo Pharma Expands Intellectual Property Portfolio with Patent Application for Exclusively Licensed Alzheimer's Drug

Silo Pharma Achieves Key Milestone with First Dosing in IND-Enabling GLP Study for SPC-15 as a Groundbreaking PTSD Treatment

Mar 26, 2025, 8:40 AM EDT - 5 months ago

Silo Pharma Achieves Key Milestone with First Dosing in IND-Enabling GLP Study for SPC-15 as a Groundbreaking PTSD Treatment

Silo Pharma Granted U.S. Patent for Novel Intranasal Post-Traumatic Stress Disorder Treatment

Feb 26, 2025, 1:30 PM EST - 6 months ago

Silo Pharma Granted U.S. Patent for Novel Intranasal Post-Traumatic Stress Disorder Treatment

Silo Pharma Expands Intellectual Property Portfolio with Provisional Patent Filing for Innovative SPC-15 Combination Treatment

Feb 18, 2025, 8:50 AM EST - 7 months ago

Silo Pharma Expands Intellectual Property Portfolio with Provisional Patent Filing for Innovative SPC-15 Combination Treatment

Silo Pharma Announces Positive Initial Pharmacokinetic, Safety, and Tolerability Study of SP-26 for Chronic Pain and Fibromyalgia

Feb 11, 2025, 7:45 AM EST - 7 months ago

Silo Pharma Announces Positive Initial Pharmacokinetic, Safety, and Tolerability Study of SP-26 for Chronic Pain and Fibromyalgia

Silo Pharma Advances Intellectual Property Portfolio with Provisional Patent Filing for PTSD Treatment

Jan 22, 2025, 8:29 AM EST - 8 months ago

Silo Pharma Advances Intellectual Property Portfolio with Provisional Patent Filing for PTSD Treatment

Silo Pharma Issues Letter to Shareholders Detailing Development Progress and Potential for Lead Assets Targeting PTSD and Chronic Pain

Jan 2, 2025, 8:45 AM EST - 8 months ago

Silo Pharma Issues Letter to Shareholders Detailing Development Progress and Potential for Lead Assets Targeting PTSD and Chronic Pain

Silo Pharma Initiates Pharmacokinetic and Tolerability Study for SP-26 Targeting Chronic Pain and Fibromyalgia

Dec 18, 2024, 7:35 AM EST - 9 months ago

Silo Pharma Initiates Pharmacokinetic and Tolerability Study for SP-26 Targeting Chronic Pain and Fibromyalgia

Silo Pharma Enters Joint Development Agreement for SP-26 Ketamine Implant Device Targeting Pain Management

Nov 29, 2024, 8:05 AM EST - 10 months ago

Silo Pharma Enters Joint Development Agreement for SP-26 Ketamine Implant Device Targeting Pain Management

Silo Pharma Announces Positive Results for Novel SPC-15 Treatment Targeting Stress-Related Disorders

Nov 18, 2024, 8:40 AM EST - 10 months ago

Silo Pharma Announces Positive Results for Novel SPC-15 Treatment Targeting Stress-Related Disorders

Silo Pharma Reports Positive Results in Sterilization and Dissolution Testing of SP-26 Ketamine Implant

Oct 31, 2024, 8:35 AM EDT - 11 months ago

Silo Pharma Reports Positive Results in Sterilization and Dissolution Testing of SP-26 Ketamine Implant

Silo Pharma Announces Completion of FDA Pre-IND Meeting to Advance Development of SPC-15 for Treatment of PTSD

Sep 10, 2024, 6:35 AM EDT - 1 year ago

Silo Pharma Announces Completion of FDA Pre-IND Meeting to Advance Development of SPC-15 for Treatment of PTSD

Silo Pharma Expands Development Agreement with Sever Pharma for Novel Ketamine Implant Therapeutic

Aug 14, 2024, 2:30 PM EDT - 1 year ago

Silo Pharma Expands Development Agreement with Sever Pharma for Novel Ketamine Implant Therapeutic

Silo Pharma Announces Partnership with Global CRO for Central Nervous System Homing Peptide

Aug 7, 2024, 8:13 AM EDT - 1 year ago

Silo Pharma Announces Partnership with Global CRO for Central Nervous System Homing Peptide

Silo Pharma to Present at H.C. Wainwright Annual Global Investment Conference

Jul 26, 2024, 8:20 AM EDT - 1 year ago

Silo Pharma to Present at H.C. Wainwright Annual Global Investment Conference

Silo Pharma Announces Closing of $2.1 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules

Jul 22, 2024, 4:45 PM EDT - 1 year ago

Silo Pharma Announces Closing of $2.1 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules

Silo Pharma Announces $2.1 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules

Jul 19, 2024, 8:01 AM EDT - 1 year ago

Silo Pharma Announces $2.1 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules

Silo Pharma Finds Partner For Device Development for Intranasal PTSD Drug

Jul 18, 2024, 12:44 PM EDT - 1 year ago

Silo Pharma Finds Partner For Device Development for Intranasal PTSD Drug

Silo Pharma and Resyca BV Partner on Device and CMC Development for Intranasal PTSD Drug SPC-15

Jul 18, 2024, 8:25 AM EDT - 1 year ago

Silo Pharma and Resyca BV Partner on Device and CMC Development for Intranasal PTSD Drug SPC-15

Why Is Nano-Cap Silo Pharma Stock Skyrocketing On Tuesday?

Jul 16, 2024, 10:50 AM EDT - 1 year ago

Why Is Nano-Cap Silo Pharma Stock Skyrocketing On Tuesday?

Silo Pharma Secures Exclusive Global License for Alzheimer's Therapeutic

Jul 16, 2024, 6:30 AM EDT - 1 year ago

Silo Pharma Secures Exclusive Global License for Alzheimer's Therapeutic

Silo Pharma Partners with AmplifyBio to Advance SPC-15 for PTSD and Anxiety

Jun 26, 2024, 8:50 AM EDT - 1 year ago

Silo Pharma Partners with AmplifyBio to Advance SPC-15 for PTSD and Anxiety

Silo Pharma Announces Successful Production of its SP-26 Ketamine Implant for Fibromyalgia

Jun 7, 2024, 8:18 AM EDT - 1 year ago

Silo Pharma Announces Successful Production of its SP-26 Ketamine Implant for Fibromyalgia

Silo Pharma Announces Closing of $2 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules

Jun 6, 2024, 4:50 PM EDT - 1 year ago

Silo Pharma Announces Closing of $2 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules

Silo Pharma Submits Pre-Investigational New Drug Application to FDA for SPC-15 as a Treatment for PTSD and Anxiety

Jun 4, 2024, 8:41 AM EDT - 1 year ago

Silo Pharma Submits Pre-Investigational New Drug Application to FDA for SPC-15 as a Treatment for PTSD and Anxiety

Silo Pharma Announces Positive Results from Study for Depression Treatment, Remission, and Relapse Prevention

May 21, 2024, 8:45 AM EDT - 1 year ago

Silo Pharma Announces Positive Results from Study for Depression Treatment, Remission, and Relapse Prevention

Silo Pharma to Participate in FDA Meeting Exploring Emerging Therapeutic Interest in Ketamine

May 14, 2024, 8:45 AM EDT - 1 year ago

Silo Pharma to Participate in FDA Meeting Exploring Emerging Therapeutic Interest in Ketamine

Silo Pharma Announces Positive Results for Intranasal PTSD Treatment

Apr 23, 2024, 8:15 AM EDT - 1 year ago

Silo Pharma Announces Positive Results for Intranasal PTSD Treatment

Silo Pharma set to Acquire Exclusive Licensing for Promising Alzheimer's Disease Therapeutic

Apr 10, 2024, 8:11 AM EDT - 1 year ago

Silo Pharma set to Acquire Exclusive Licensing for Promising Alzheimer's Disease Therapeutic

Silo Pharma Files Patent for Groundbreaking Ketamine Implant Therapeutic to Target Fibromyalgia and Chronic Pain

Mar 18, 2024, 7:15 AM EDT - 1 year ago

Silo Pharma Files Patent for Groundbreaking Ketamine Implant Therapeutic to Target Fibromyalgia and Chronic Pain

Silo Pharma Completes Successful Dose-Ranging Study of SPC-15 Intranasal Therapeutic for PTSD

Feb 28, 2024, 8:25 AM EST - 1 year ago

Silo Pharma Completes Successful Dose-Ranging Study of SPC-15 Intranasal Therapeutic for PTSD

Silo Pharma's SP-26 Ketamine Implant Demonstrates Successful Drug Delivery

Feb 14, 2024, 8:45 AM EST - 1 year ago

Silo Pharma's SP-26 Ketamine Implant Demonstrates Successful Drug Delivery

Silo Pharma Announces Pipeline Prioritization for 2024 Targeting Mental Health, Chronic Pain, and Neurology

Feb 1, 2024, 10:00 AM EST - 1 year ago

Silo Pharma Announces Pipeline Prioritization for 2024 Targeting Mental Health, Chronic Pain, and Neurology

Silo Pharma Announces Positive Results in Alzheimer's Disease Study

Jan 24, 2024, 8:55 AM EST - 1 year ago

Silo Pharma Announces Positive Results in Alzheimer's Disease Study

RealYOW
RealYOW Sep. 6 at 4:14 AM
$SILO who dat?
0 · Reply
DocHooli
DocHooli Sep. 5 at 10:16 PM
$SILO is my lead candidate for the Galaxy, Jump Crypto, and Multicoin Solana DAT. Establishing a crypto advisory board with Corwin Yu who does business with all major exchanges including $GLXY he understands how DATs work. No debt, no significant shareholders, very decent smart board people already. Obviously this is my thinking it makes sense to me but maybe not for the leaders of those companies. It’s very narrow though there are only maybe 6 potential take over targets below a 30Mil market cap. This one is top for sure.
1 · Reply
Jbjb90
Jbjb90 Sep. 3 at 3:44 PM
$SILO https://www.stocktitan.net/news/SILO/silo-pharma-secures-australian-patent-covering-licensed-ptsd-drug-1433dpdh3807.html
0 · Reply
onestudy
onestudy Sep. 3 at 1:36 PM
$SILO Patent news out on the company website this morning for its intranasal PTSD drug. 💪🚀
0 · Reply
premarketmaker
premarketmaker Sep. 3 at 12:28 PM
$SILO .715 PM HOD
0 · Reply
Thestocktraderhubzee
Thestocktraderhubzee Sep. 3 at 12:26 PM
$SILO Silo Pharma Secures Patent For PTSD Treatment SPC-15 Through Columbia University Partnership
0 · Reply
NVDAMillionaire
NVDAMillionaire Sep. 3 at 9:20 AM
$SILO Outstanding article that hits the mark on SILO's current state. So if you want to refresh your SILO insights or learn about SILO from scratch, this is a must read. https://beyondspx.com/quote/SILO/silo-pharma-s-bold-convergence-psychedelic-innovation-meets-digital-asset-ambition-nasdaq-silo#analysis
0 · Reply
onestudy
onestudy Sep. 2 at 12:41 PM
$SILO Elon Musk’s "DOGE lieutenant" took over Lykos, the US’s largest MDMA company, which aims to bring a psychedelic drug for PTSD to market under the Trump administration (The Guardian, Aug 28, 2025). $SILO is getting ready to submit IND application for its psychedelic based PTSD drug and has a connection with the Department of Veterans Affairs through the recent HOTH partnership.
0 · Reply
onestudy
onestudy Sep. 1 at 10:53 AM
$SILO Oregon Psilocybin Services (OPS), created under the Oregon Psilocybin Services Act, is moving forward with its 2025 rulemaking process. Key dates for psychedelic-related plays: 📝 Written Public Comment Period: Sept 2 – Sept 22, 2025 📢 Public Hearings: Sept 16 & Sept 18, 2025
0 · Reply
onestudy
onestudy Aug. 31 at 10:35 PM
$SILO Psychedelic drug, psilocybin, can reshape brain networks linked to negative thoughts, offering powerful potential for mental health treatments. From "New Scientist" (Aug 29, 2025)
0 · Reply
onestudy
onestudy Aug. 28 at 5:35 PM
$SILO I found that Silo’s silocrypto.com has a service worker running as of today. That shows it’s being built behind the scenes as a PWA-style (Progressive Web App) crypto site, designed for scalability and interactive features. In other words, there’s already real code running in the background of the "Launching Soon" page. For today’s market trending list, $OPAD takes the #1 spot, soaring over 70% on talk of a potential short squeeze and comparisons to OpenDoor. $SNAP is drawing massive attention with speculation about a buyout and its AR glasses project. ALTS is also trending on the WLFI token launch and potential partnerships. Lastly, today’s #2 trending stock, $SOGP short squeezed hard — popping over 150% following news of a share repurchase program!
0 · Reply
onestudy
onestudy Aug. 28 at 12:04 PM
$SILO Short volume spiked to 82.44%. Potential short squeeze when buying pressure picks up.
0 · Reply
onestudy
onestudy Aug. 27 at 3:21 PM
$SILO In 2–3 weeks, the device study results for the microchip-based nasal spray system should arrive: The July 16, 2025 press release said results were "expected within 60 days," which puts the deadline around Sept 15. We already got the animal study update on Aug 19, so the next big catalyst for $SILO is the device study. With August almost over, the timing lines up for that data to drop in the next 2–3 weeks.
0 · Reply
onestudy
onestudy Aug. 26 at 11:10 PM
$SILO 🚨 Update on $SILO’s silocrypto.com 🚨 SILO is hosting silocrypto.com on Amazon’s AWS cloud infrastructure — one of the most reliable and scalable hosting solutions in the world. With AWS Global Accelerator, the site is being optimized for speed, security, and global accessibility. IMO, hosting on AWS from $AMZN proves SILO is serious about building a professional, enterprise-grade crypto platform — not just testing the waters.
0 · Reply
onestudy
onestudy Aug. 26 at 5:05 PM
$SILO 👉 Psychedelics ETF $PSIL increased its stake in $SILO by 48.3%, now holding 184,236 shares, as reported on August 25, 2025. 🚀🚀
0 · Reply
onestudy
onestudy Aug. 25 at 7:28 PM
$SILO SILO’s Alzheimer’s psychedelic drug news was published 4 days ago, according to StockTitan’s Reddit post.
1 · Reply
Jbjb90
Jbjb90 Aug. 25 at 6:13 PM
$SILO https://www.stocktitan.net/news/SILO/silo-pharma-s-alzheimer-s-candidate-spc-14-featured-in-leading-r3z66swynrdj.html
1 · Reply
counter
counter Aug. 25 at 3:51 PM
$SILO between crypto and biotech the company gets confusing...whats our next catalyst waiting for?
2 · Reply
onestudy
onestudy Aug. 25 at 12:10 PM
$SILO SILO's "silocrypto.com" launching soon!
0 · Reply
onestudy
onestudy Aug. 23 at 2:58 PM
$SILO SILO has enough cash to operate for at least the next 12 months (page 27 of their 10-Q filed on Aug 13, 2025).
0 · Reply
onestudy
onestudy Aug. 22 at 3:36 PM
$SILO SILO is building a crypto website and is in the process of naming two more members to its Crypto Advisory Board. Today’s market is showing cryptos coming back stronger once again. $XRP.X is topping the trending list on possible rate cuts, steadily climbing throughout the day. The monster crypto $ETH.X is roaring back, soaring more than $400 at the time of writing. Meanwhile, $SOFI is breaking out and looks ready to cross the $25 mark on its way toward $30. Another top-trending stock is $NIO which is enjoying a strong multi-day run after opening preorders for its largest battery-based electric SUV, set to launch in September.
1 · Reply
onestudy
onestudy Aug. 22 at 1:10 AM
$SILO Today, Aug 21, 2025, SILO announced that its Alzheimer’s drug candidate, SPC-14, has shown promising preclinical results in a peer-reviewed research paper. This psychedelic-based drug was developed under a sponsored research agreement with Columbia University. Most importantly, $SILO holds an exclusive global license with Columbia, granting full rights to develop, manufacture, and commercialize SPC-14.
0 · Reply